Deadly fungal infections are becoming resistant to common treatments, but a team of researchers from USC and from France have found a potential innovative solution.
Each year, invasive fungal infections sicken an estimated 2 million people worldwide and kill nearly 800,000 – but a team of international scientists have discovered a new approach for antifungal drug treatments.
Researchers from USC and France identified that a gene-regulating protein, Bdf1, is critical for the survival of the pathogenic fungus, Candida albicans.
“We have shown that Bdf1 is an important new target for drug design,” said Charles McKenna, a senior author of the study who is a professor of chemistry and pharmaceutical sciences in the USC Dornsife College of Letters, Arts and Sciences. “Our findings show that compounds that bind to this target will disrupt the growth of the fungus, opening the way to novel drug treatments for fungal disease.”
The French scientists who led the study with McKenna were Jérôme Govin and Carlo Petosa, both at the University of Grenoble Alpes.
Rising health threat
The fungus, C. albicans, is an aggressive pathogen that in healthy individuals is normally held in check by the immune system. However, people with a weakened immune system, including patients who have cancer, HIV or autoimmune diseases, are susceptible to the infection, which can be life-threatening, McKenna said.
The team’s findings, published on May 18 in the journal Nature Communications, may prove timely. Fungal infections such as candidiasis are increasingly resistant to drug treatments.
Each year, an estimated 46,000 patients in the United States become infected with invasive candidiasis, according to the Centers for Disease Control and Prevention.
“When susceptible people develop candida infections, the fungus may enter the bloodstream. If treatment is unsuccessful, it has a very high mortality rate – in the 40 percent range,” McKenna said. “We have a very limited number of drugs that are effective in treating such systemic infections. Unfortunately, like many other pathogens, C. albicans is increasingly resistant to the few available drugs, raising the stakes for patients, and fresh approaches are urgently needed.”
The Latest on: Antifungal drug treatments
FDA's efforts to foster discovery and development of new tools to fight antimicrobial-resistant infections
on June 13, 2018 at 9:40 pm
To that end, one step being taken is implementing a set of special incentives that Congress developed for antibacterial and antifungal drugs that treat serious or life-threatening infections. Gottlieb explains that under the program, new drug applications ... […]
No link found between oral antifungal drug and stillbirth
on June 13, 2018 at 7:31 am
New research from a Swedish and Norwegian team of researchers led from Karolinska Institutet does not support a suggested link between treatment with the oral antifungal drug fluconazole during pregnancy and an increased risk of stillbirth. The study is ... […]
FDA Issues Draft Guidance to Aid Development of Critical Drugs
on June 13, 2018 at 1:08 am
... U.S. Food and Drug Administration has issued a draft guidance to help companies develop drugs using the Limited Population Pathway for Antibacterial and Antifungal Drugs, also known as the LPAD pathway, which was established by Congress under the 21st ... […]
Pharmaceutical makers sending drug-spiked water to treatment plants
on June 12, 2018 at 7:15 pm
In one extreme example, an antifungal drug was found at levels 3,000 times higher at a treatment plant near a drug maker compared with treatment plants that do not accept drug maker discharge. Published in Science of the Total Environment, the ... […]
FDA considers changing reimbursement model for new antimicrobial drugs
on June 12, 2018 at 1:02 pm
The FDA also issued a draft guidance to assist the development of drugs using the Limited Population Pathway for Antibacterial and Antifungal Drugs, (LPAD) pathway, which was established by Congress under the 21st Century Cures Act. “The FDA believes ... […]
Antifungal drug eliminates bowel cancer
on June 4, 2018 at 11:41 am
We’ve targeted a type of cell that lies asleep within bowel tumours, remaining unresponsive to treatment and putting the patient at risk of their cancer coming back”. “What’s interesting is that this drug seems to kick both dormant and non-dormant ... […]
Antifungal drug kills dormant colorectal cancer cells
on June 3, 2018 at 12:04 am
Though various treatments are available for it, certain tumor cells are therapy-resistant. Now, research suggests that an antifungal drug may be effective against these persistent cells. But researchers from the Cancer Research UK Cambridge Institute have ... […]
Antifungal drug eliminates dormant bowel cancer cells in mice
on June 1, 2018 at 1:27 pm
June 1 (UPI) --An antifungal medication commonly prescribed to treat toenail ... These "sleeping" cells are resistant to drugs, including chemotherapy, and can later awaken after treatment has finished and lead to the tumors regrowing. […]
Can you treat vulvovaginitis at home?
on June 1, 2018 at 11:13 am
Medications, such as metronidazole (available as a tablet or gel) or clindamycin (a cream) are only available with a doctor's prescription. Yeast infection treatments Treating yeast infections can be done with over-the-counter (OTC) antifungal creams and ... […]
Antifungal drug eliminates sleeping bowel cancer cells in mice
on May 31, 2018 at 5:39 pm
An antifungal medication, commonly prescribed for toenail infections ... These 'sleeping' cells are resistant to drugs, including chemotherapy, which work by targeting cells that are actively growing. So even if it looks like a treatment has worked ... […]
via Google News and Bing News